NovaGo Therapeutics, a clinical-stage biotech company based in Schlieren, Switzerland, said on 2 September 2026 that it had closed a Series B financing round of CHF 24m (about $30m).
The round was co-led by Neurimmune and Pureos Bioventures, with existing and new investors also taking part. NovaGo did not name the other participants and did not disclose a valuation.
Alongside the equity, the company received non-dilutive funding from two foundations, the Swiss Paraplegic Foundation and Wings for Life, a spinal cord research foundation. The size of those grants was not disclosed.
“We are excited to see this program progress into this critical stage of clinical testing, bringing us a meaningful step closer to a much-needed treatment for patients living with the consequences of spinal cord injury.”Prof. Martin Schwab, Chief Scientific Officer, NovaGo Therapeutics
What NovaGo Therapeutics does
NovaGo develops biologic drugs aimed at Nogo-A, a protein that blocks the regrowth of nerve fibres and limits neuroplasticity in the brain and spinal cord. The idea is that blocking Nogo-A could help damaged nerves regrow and allow patients to recover some lost function.
Spinal cord injury is the company's lead indication, but it is also working on anti-Nogo-A approaches for stroke and secondary progressive multiple sclerosis. The company said there are currently no approved regenerative treatments that restore neurological function lost after a spinal cord injury.
According to the release, the company was built on earlier research into Nogo-A as an inhibitor of nerve regeneration. Its chief scientific officer is Prof. Martin Schwab, and its chief executive is Stefan Moese. The release did not give a founding year or headcount.
What the money is for
The proceeds will take NovaGo's lead programme into a proof-of-concept study in patients with acute spinal cord injury. The trial is randomised and double-blind and will enrol 120 patients at sites in Germany, Spain and Switzerland.
The company did not give a timeline for enrolment or for first results. In its announcement, NovaGo said the goal is to deliver the first regenerative treatment for people with acute spinal cord injury.
Schwab said the programme was moving into a critical stage of clinical testing. Moese thanked the investors and the two foundations, saying their support made it possible to go ahead with the study.
Who invested
Neurimmune is a clinical-stage Swiss biopharmaceutical company that develops antibody therapies, mostly for diseases linked to protein aggregation such as Alzheimer's disease, ALS and ATTR cardiomyopathy. Its pipeline includes NG004, an anti-Nogo-A antibody for spinal cord injury that is in Phase 1. Neurimmune president and chief executive Prof. Roger M. Nitsch sits on NovaGo's board. Its most advanced programme, the anti-ATTR antibody cliramitug, is in Phase 3 for ATTR cardiomyopathy.
Nitsch described the treatment as a fully human antibody designed to promote nerve outgrowth after injury and said Neurimmune was encouraged by the Phase 1 results with NG004.
Pureos Bioventures is a venture fund advised by Swiss firm Pureos Partners that invests only in private drug developers. Managing partner Dominik Escher said the fund saw the Phase 1 results in spinal cord injury as encouraging. Its portfolio spans oncology, immunology, ophthalmology, rare diseases and neuroscience.
NovaGo's release did not mention any earlier funding rounds, so the company's total funding to date is not known.
Company website: novagotherapeutics.com